Fred Hirsch, Execuitive Director, Center for Thoracic Oncology, Tisch Cancer Institute at Mount Sinai, shared on LinkedIn
“Great 8- year update from adjuvant EGFR therapy in NSCLC ( Audura study).
- HR – 0.53
- 8 Year survival: 74% vs 58%.
Who will benefit and who will not?”
To which Ola Khorshid, Department Chair Medical Oncology and Malignant Hematology at NCI Cairo University, added:
“Great reassuring update.”
Find out more:
Osimertinib Shows Sustained 8-Year Survival Benefit in Early-Stage EGFR-Mutated NSCLC in ADAURA
